Tag: Prescription Drugs

Improved median overall survival and progression-free survival seen for pegargiminase-based chemotherapy

Fewer patients progressed to rheumatoid arthritis versus those receiving placebo

Rusfertide reduces number of phlebotomies and maintains hematocrit at less than 45 percent

Significant reductions seen in mean Physician Global Assessment scores and in pain, C-reactive protein, IL-6, leukocytes

Significant reduction seen in systolic blood pressure with zilebesiran 150, 300, 600 mg once in six months; 300 mg once every three months

Hydrochlorothiazide plus beta blockers recommended for patients with hypertension prior to BTKi initiation

Cefepime-taniborbactam superior for composite success, which included microbiologic and clinical success

Generally favorable effect seen in terms of number of new gadolinium-enhancing T1-weighted lesions at week 12

Percentage of patients with PASI-75 response was higher with the interleukin-23-receptor antagonist peptide

Resmetirom 80 mg and 100 mg better than placebo for patients with NASH and fibrosis stage F1B, F2, F3